We have learned how to stop hepatitis B from spreading, but not yet how to reach everyone who needs treatment.
The World Health Organization has delivered a report that holds both hope and warning in equal measure: a 32 percent decline in new hepatitis B infections demonstrates that sustained public health investment can change the course of a disease, yet 1.3 million deaths in a single year remind us that prevention and treatment are not the same gift. The burden falls heaviest on ten nations — Nigeria among them — where health systems strain under the weight of infections acquired long before vaccines arrived. Humanity has learned, it seems, how to slow the river at its source, but has not yet built enough boats for those already caught in the current.
- Despite a landmark 32% drop in new hepatitis B infections, 1.3 million people still died from hepatitis B and C in 2024 — proof that prevention gains have not translated into lives saved for those already infected.
- Ten countries, led by Nigeria, carry 70% of the world's hepatitis B deaths, exposing a brutal geographic inequality that aggregate global statistics quietly obscure.
- The WHO has issued a direct warning: the world is not moving fast enough to meet its 2030 hepatitis elimination targets, even as those targets fall short of full eradication.
- The critical bottleneck is treatment access — antiviral drugs, medical monitoring, and healthcare infrastructure remain out of reach for millions living with chronic infection in high-burden nations.
- Scaled-up funding, political commitment, and cross-border coordination are now the variables on which the 2030 deadline — and millions of lives — will turn.
The World Health Organization this week released figures showing that global efforts to contain hepatitis B have produced real, measurable results. New infections have fallen by 32 percent — a decline built on years of vaccination campaigns, screening programs, and expanded access to prevention tools. It is the kind of progress that demonstrates sustained investment in public health can move the needle.
Yet the same report carries an urgent warning. In 2024, hepatitis B and C together killed 1.3 million people. That death toll has not fallen in step with infection rates, exposing a stubborn gap between preventing new cases and saving those already living with the virus. The WHO is now sounding an alarm: at the current pace, the world will not meet its 2030 hepatitis elimination targets — benchmarks that call not for eradication, but for specific reductions in infections and deaths. Even those modest goals are now at risk.
The burden is not evenly shared. Ten countries account for 70 percent of all hepatitis B deaths worldwide, with Nigeria at the top of the list. For people in these nations, the global headline — a 32 percent drop in infections — masks a far starker reality. Hepatitis B screening and antiviral treatment, routine in wealthier countries, remain out of reach for many in these high-burden regions.
Vaccination has worked. But it cannot save the 1.3 million who died last year from infections acquired years or decades before vaccination rates climbed. Reaching those people requires antiviral drugs, regular monitoring, and healthcare infrastructure that many countries simply do not have. The WHO's call to action is clear: scale up treatment access and intensify vaccination in the ten countries where hepatitis B kills the most. Whether the world can summon the money, political will, and coordination to do it in time remains the open question on which millions of lives depend.
The World Health Organization released figures this week showing that the global effort to contain hepatitis B has produced measurable results. New infections have fallen by nearly a third over the period the agency tracked—a 32 percent decline that reflects years of vaccination campaigns, screening programs, and improved access to prevention tools across dozens of countries. It is real progress, the kind that public health officials point to when they need to show that sustained investment in disease control can move the needle.
Yet the same report that celebrates this decline carries an urgent warning. In 2024 alone, hepatitis B and C together killed 1.3 million people worldwide. That number has not fallen in step with infection rates, and it reveals a stubborn gap between preventing new cases and saving the lives of those already infected. The WHO is now sounding an alarm: at the current pace of progress, the world will not meet its 2030 targets for hepatitis elimination. The targets themselves are modest by some measures—they call for reducing new infections and deaths by specific percentages, not eradicating the disease entirely. But even those benchmarks are now at risk.
The burden of hepatitis B death is not evenly distributed across the globe. Ten countries account for 70 percent of all hepatitis B deaths worldwide. Nigeria leads this list, joined by nine others whose names the WHO has identified but whose health systems often lack the resources to scale up treatment and vaccination at the speed required. This concentration of mortality in a small number of nations means that the global picture—a 32 percent drop in infections—masks a much starker reality for people living in those high-burden regions. A person in one of these ten countries faces a vastly different risk landscape than someone in a country where hepatitis B screening and antiviral treatment are routine.
The gap between prevention and treatment is the core problem. Vaccination has worked. The decline in new infections proves it. But vaccination alone does not save the 1.3 million people who died last year. Those deaths came from hepatitis B and C infections acquired years or decades earlier, before vaccination rates climbed, or in populations that vaccination campaigns have not yet reached. Treating people who already carry the virus requires access to antiviral drugs, regular medical monitoring, and healthcare infrastructure that many countries simply do not have. The WHO's warning is essentially this: we have learned how to stop hepatitis B from spreading, but we have not yet learned how to reach everyone who needs treatment.
What happens next will determine whether the 2030 targets become a rallying point for renewed action or a missed milestone that recedes into the past. The WHO is calling for scaled-up treatment access and intensified vaccination in the ten countries where hepatitis B kills the most people. That means money, political will, and coordination across borders. It means training healthcare workers, securing drug supplies, and building the systems to find people with chronic hepatitis B infection and bring them into care. The 32 percent drop in new infections shows it can be done. Whether the world can do it fast enough for the people who are already sick remains an open question.
Notable Quotes
Current pace of progress is insufficient to meet 2030 elimination targets— World Health Organization
The Hearth Conversation Another angle on the story
A 32 percent drop sounds like real progress. Why is the WHO worried about missing 2030 targets?
Because preventing new infections and saving people who are already infected are two different problems. The vaccine works—that's why infections fell. But 1.3 million people died last year from hepatitis B and C. Those are people who got infected before or outside the reach of vaccination campaigns. They need treatment, not prevention.
So the vaccine is only part of the solution.
Exactly. It's the easier part, in some ways. You vaccinate babies and high-risk groups, and over time, new infections drop. But the people living with chronic hepatitis B right now—they need antiviral drugs, monitoring, access to doctors. That infrastructure doesn't exist in the places where it's needed most.
You mentioned ten countries account for 70 percent of deaths. Why those countries?
Geography, economics, healthcare capacity. Nigeria and the nine others have large populations with high rates of hepatitis B, but they also have weaker health systems. Fewer people get screened. Fewer people who are diagnosed get access to treatment. It's not that the virus is different there—it's that the systems to fight it are stretched thin.
What would it take to hit the 2030 targets?
Money, mainly. Drugs, training, infrastructure. The WHO is saying the current pace isn't enough. You'd need to accelerate treatment access in those ten countries specifically, not just keep doing what's working globally. It's a different kind of work than vaccination.
Is there any reason to think it will happen?
The 32 percent drop shows that sustained effort works. But whether governments and donors will prioritize treatment access the way they've prioritized vaccination—that's the real question.